New Findings from EpicentRx Inc. Describe Advances in Cancer Gene Therapy (Beta Prime: a First-in-man Phase 1 Study of Adapt-001, an Armed Oncolytic Adenovirus for Solid Tumors)

  • Christopher Larson

Press/Media

Period26 Jan 2024

Media coverage

1

Media coverage

  • TitleNew Findings from EpicentRx Inc. Describe Advances in Cancer Gene Therapy (Beta Prime: a First-in-man Phase 1 Study of Adapt-001, an Armed Oncolytic Adenovirus for Solid Tumors)
    Media name/outletCancer Gene Therapy Daily
    Country/TerritoryUnited States
    Date26/01/24
    PersonsChristopher Larson
View all 1
View less

Related content